

## ASX ANNOUNCEMENT MARKET RELEASE

17 June 2022

### CONFERENCE CALL – UPDATE ON US FDA APPLICATION

---

Australian medical technology company, Artrya Limited (ASX: AYA, Artrya or the Company) advises it will be holding an investor and analyst conference call discussing the update on the US FDA Application at 10am AEST (8am AWST) on Monday 20 June 2022.

Join the conference call on Zoom by [clicking here](#).

*This announcement was approved by the Company's Managing Director, John Barrington, on behalf of the Artrya Board.*

For further information please contact:

Investor Enquiries:  
John Barrington  
Artrya Limited  
+61 419 850 502  
[investors@artrya.com](mailto:investors@artrya.com)

Media Enquiries:  
Felicity Heath  
Daymark  
+61 457 196 603  
[felicity.heath@daymark.com.au](mailto:felicity.heath@daymark.com.au)

#### About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA). Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary artery disease and develop a holistic overview of a patient at risk. Artrya has developed deep learning algorithms that will streamline how heart disease care is delivered. Artrya USA Inc. is a wholly owned subsidiary of Artrya Limited.

For more information: [www.artrya.com](http://www.artrya.com)